Upgrade to SI Premium - Free Trial

BofA Securities Reiterates Neutral Rating on Agilent (A) following Biocare Medical acquisition announcement

March 9, 2026 9:27 AM
BofA Securities analyst Michael Ryskin reiterated a Neutral rating and $150.00 price target on Agilent (NYSE: A)The analyst commented, "Earlier ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments